Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer
Merck has been in the FDA’s crosshairs over accelerated approvals for PD-(L)1 inhibitor Keytruda that have whiffed in confirmatory studies. One of those speedy nods, a pairing with TKI inhibitor Lenvima from Eisai in endometrial cancer, has now scored a much-needed OS win to back up its case.
The Keytruda-Lenvima combo nailed its primary progression-free survival and OS endpoints in an open-label Phase III study in advanced, metastatic or recurrent endometrial cancer patients after chemotherapy, according to data presented Friday at the virtual Society of Gynecologic Oncology annual meeting.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.